TY - JOUR
T1 - Management of SIADH-related hyponatremia due to psychotropic medications – An expert consensus from the Association of Medicine and Psychiatry
AU - Pinkhasov, Aaron
AU - Xiong, Glen
AU - Bourgeois, James A.
AU - Heinrich, Thomas W.
AU - Huang, Heather
AU - Coriolan, Shanice
AU - Annamalai, Aniyizhai
AU - Mangal, Jed P.
AU - Frankel, Steven
AU - Lang, Michael
AU - Raj, Y. Pritham
AU - Dandois, Matthew
AU - Barth, Kelly
AU - Stewart, Anne Louise
AU - Rado, Jeffrey
AU - Pesek, Justin
AU - Sanders, Aaron
AU - Spearman-McCarthy, E. Vanessa
AU - Gagliardi, Jane
AU - Fiedorowicz, Jess G.
N1 - Funding Information:
We thank Johnathan Pinkhasov, PharmD, MS, MBA for the algorithm's graphic designs (Figs. 1 and 2) and Leela Sathyaputri for her assistance with literature review for the antipsychotics and mood stabilizers section. We also would like to express our gratitude to Nobuyuki Miyawaki, MD, chief of Nephrology Division at NYU Langone Hospital – Long Island for his invaluable critique and suggestions in the management section.
Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - Objective: Hyponatremia is the most common electrolyte imbalance encountered in clinical practice and is associated with negative healthcare outcomes and cost. SIADH is thought to account for one third of all hyponatremia cases and is typically an insidious process. Psychotropic medications are commonly implicated in the etiology of drug induced SIADH. There is limited guidance for clinicians on management of psychotropic-induced SIADH. Methods: After an extensive review of the existing literature, clinical-educators from the Association of Medicine and Psychiatry developed expert consensus recommendations for management of psychotropic-induced SIADH. A risk score was proposed based on risk factors for SIADH to guide clinical decision-making. Results: SSRIs, SNRIs, antipsychotics, carbamazepine, and oxcarbazepine have moderate to high level of evidence demonstrating their association with SIADH. Evaluation for an avoidance of medications that cause hyponatremia is particularly important. Substitution with medication that is less likely to cause SIADH should be considered when appropriate. We propose an algorithmic approach to monitoring hyponatremia with SIADH and corresponding treatment depending on symptom severity. Conclusions: The proposed algorithm can help clinicians in determining whether psychotropic medication should be stopped, reduced or substituted where SIADH is suspected with recommendations for sodium (Na+) monitoring. These recommendations preserve a role for clinical judgment in the management of hyponatremia with consideration of the risks and benefits, which may be particularly relevant for complex patients that present with medical and psychiatric comorbidities. Further studies are needed to determine whether baseline and serial Na+ monitoring reduces morbidity and mortality.
AB - Objective: Hyponatremia is the most common electrolyte imbalance encountered in clinical practice and is associated with negative healthcare outcomes and cost. SIADH is thought to account for one third of all hyponatremia cases and is typically an insidious process. Psychotropic medications are commonly implicated in the etiology of drug induced SIADH. There is limited guidance for clinicians on management of psychotropic-induced SIADH. Methods: After an extensive review of the existing literature, clinical-educators from the Association of Medicine and Psychiatry developed expert consensus recommendations for management of psychotropic-induced SIADH. A risk score was proposed based on risk factors for SIADH to guide clinical decision-making. Results: SSRIs, SNRIs, antipsychotics, carbamazepine, and oxcarbazepine have moderate to high level of evidence demonstrating their association with SIADH. Evaluation for an avoidance of medications that cause hyponatremia is particularly important. Substitution with medication that is less likely to cause SIADH should be considered when appropriate. We propose an algorithmic approach to monitoring hyponatremia with SIADH and corresponding treatment depending on symptom severity. Conclusions: The proposed algorithm can help clinicians in determining whether psychotropic medication should be stopped, reduced or substituted where SIADH is suspected with recommendations for sodium (Na+) monitoring. These recommendations preserve a role for clinical judgment in the management of hyponatremia with consideration of the risks and benefits, which may be particularly relevant for complex patients that present with medical and psychiatric comorbidities. Further studies are needed to determine whether baseline and serial Na+ monitoring reduces morbidity and mortality.
KW - Antidepressants
KW - Antipsychotics
KW - Hyponatremia
KW - Mood stabilizers
KW - Psychoactive medications
KW - SIADH
UR - http://www.scopus.com/inward/record.url?scp=85118328539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118328539&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychores.2021.110654
DO - 10.1016/j.jpsychores.2021.110654
M3 - Article
C2 - 34739943
AN - SCOPUS:85118328539
SN - 0022-3999
VL - 151
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
M1 - 110654
ER -